Journal of the American Society of Nephrology
2006 JASN IMPACT FACTOR 7.371 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on March 27, 2008
Journal of the American Society of Nephrology
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2007101128
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Ritz, E.
Right arrow Articles by Wanner, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ritz, E.
Right arrow Articles by Wanner, C.


UP FRONT MATTERS: Brief Review

Lipid Abnormalities and Cardiovascular Risk in Renal Disease

Eberhard Ritz 1 and Christoph Wanner

Department of Internal Medicine, Division of Nephrology, University of Heidelberg, Heidelberg, Germany; and Department of Internal Medicine, Division of Nephrology, University of Würzburg, Würzburg, Germany


1 To whom correspondence should be addressed. E-mail: prof.e.ritz{at}t-online.de.


   Abstract

The recent 4D study failed to provide definitive evidence for benefit of statin use in type 2 diabetics on dialysis. This finding stands in stark contrast to a number of other observations in patients with early stages of chronic kidney disease where substantial benefit of statins had been documented. Here we discuss some potential explanations for the unexpected finding of the 4D study and for the negative association between below average total cholesterol and vascular mortality among dialysis patients. Admittedly, in the absence of definite evidence in dialysis patients, we still conclude that the administration of statins is appropriate in patients with manifest coronary disease.







HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP